Trials / Not Yet Recruiting
Not Yet RecruitingNCT07115654
BCMA/CD3 BsAb Therapy for POEMS Syndrome
A Prospective Single-Arm Clinical Trial of BCMA/CD3 BsAb Therapy for POEMS Syndrome
- Status
- Not Yet Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 10 (estimated)
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China · Academic / Other
- Sex
- All
- Age
- 18 Years – 78 Years
- Healthy volunteers
- Not accepted
Summary
This is a prospective, single-arm, investigator-initiated clinical trial evaluating the safety and efficacy of a BCMA/CD3 bispecific antibody (CM336) in patients with POEMS syndrome.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CM336 (BCMA/CD3 bispecific antibody) | CM336 is a bispecific antibody targeting BCMA and CD3, designed to redirect T cells to eliminate abnormal plasma cells. |
Timeline
- Start date
- 2025-08-10
- Primary completion
- 2026-12-01
- Completion
- 2027-12-01
- First posted
- 2025-08-11
- Last updated
- 2025-08-11
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT07115654. Inclusion in this directory is not an endorsement.